Compare AUROW & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUROW | KTTA |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 18.1M |
| IPO Year | 2021 | 2021 |
| Metric | AUROW | KTTA |
|---|---|---|
| Price | $0.04 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 25.2K | ★ 206.4K |
| Earning Date | 04-30-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.35 | ★ 77.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,000,000.00 | $486,559.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3130.37 |
| 52 Week Low | $0.02 | $0.28 |
| 52 Week High | $0.87 | $2.06 |
| Indicator | AUROW | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 51.42 |
| Support Level | N/A | $0.48 |
| Resistance Level | $0.08 | $0.60 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 12.71 | 44.29 |
Aurora Innovation is a US autonomous driving provider for heavy trucks. The company produces and sells its Aurora Driver system, which includes hardware installed in a vehicle, software to autonomously drive it, and data management to maintain and improve the software. Aurora targets long-haul routes. The company currently offers its trucking-as-a-service model, where it owns and operates the trucks and makes deliveries for customers. The company plans to start selling its driver-as-a-service model next year, where fleet owners will own the trucks and Aurora's software will operate them.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.